Among Type B (Bizarre) adverse drug reactions, which of the following is the most common organ system affected in drug-induced idiosyncratic reactions?

Explanation

## Type B (Bizarre) Adverse Drug Reactions — Organ System Distribution **Key Point:** The liver is the most common organ affected in Type B (idiosyncratic) adverse drug reactions, accounting for the majority of drug-induced liver injury (DILI) cases in clinical practice. ### Why the Liver is Most Vulnerable 1. **Metabolic Hub:** The liver is the primary site of drug metabolism (Phase I, II, III reactions). Reactive metabolites generated during metabolism can cause hepatotoxicity. 2. **Genetic Polymorphisms:** Variations in cytochrome P450 enzymes (CYP2D6, CYP2C9, etc.) and phase II enzymes (NAT, TPMT) predispose certain individuals to idiosyncratic hepatotoxicity. 3. **Immune-Mediated Injury:** Type B reactions often involve immune mechanisms (hapten formation, T-cell activation), and the liver's rich immune cell population makes it a target. 4. **High Drug Exposure:** The liver receives blood from both the hepatic artery and portal vein, resulting in high drug concentrations. ### Common Type B Hepatotoxic Drugs | Drug Class | Examples | Mechanism | |---|---|---| | **Antibiotics** | Amoxicillin-clavulanate, isoniazid, trimethoprim-sulfamethoxazole | Immune-mediated hepatitis | | **Anticonvulsants** | Phenytoin, carbamazepine | Reactive metabolite formation | | **NSAIDs** | Diclofenac, ibuprofen | Idiosyncratic DILI | | **Antituberculosis** | Rifampicin, isoniazid, pyrazinamide | Metabolite-induced injury | | **Statins** | Atorvastatin, simvastatin | Rare idiosyncratic hepatotoxicity | ### Frequency of Type B Reactions by Organ **High-Yield:** Liver accounts for ~40–50% of all Type B reactions, followed by bone marrow (~20–25%), skin (~15–20%), and kidneys (~10–15%). ### Key Features of Type B Hepatotoxicity - **Unpredictable:** No dose–response relationship - **Immune-mediated:** Often accompanied by fever, rash, eosinophilia, or lymphocytosis - **Delayed onset:** Typically appears after 1–6 weeks of therapy - **Irreversible:** Can progress to acute liver failure or cirrhosis - **Rare:** Occurs in <1 per 10,000 exposed individuals **Clinical Pearl:** Always check baseline LFTs before starting drugs known for idiosyncratic hepatotoxicity (e.g., isoniazid, amoxicillin-clavulanate, anticonvulsants) and monitor periodically during therapy.